Expertise in
10
conditions

Dr. Kai He

Oncology
Ohio State University Hospital-Pavilion
300 W 10th Ave, 
Columbus, OH 
Offers Telehealth
Expertise in
10
conditions
Ohio State University Hospital-Pavilion
300 W 10th Ave, 
Columbus, OH 

Overview

Kai He is an Oncologist practicing medicine in Columbus, Ohio.

Dr. He is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and ALK-Positive Non-Small Cell Lung Cancer.

He is actively involved in clinical research, co-authoring 16 peer reviewed articles and participating in 6 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in TX

Hospital Affiliations

Ohio State University State Health System

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

Ohio State University Hospital-Pavilion
300 W 10th Ave, Columbus, OH 43210

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase I Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE A10ᶜ⁷⁹⁶T in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
A Phase I Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE A10ᶜ⁷⁹⁶T in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: December 09, 2025
Intervention Type: Biological
Study Phase: Phase 1
A Multicenter, Open-label Rollover Study of Sitravatinib Alone or in Combination With Other Anticancer Therapies in Patients With Advanced or Metastatic Solid Malignancies
A Multicenter, Open-label Rollover Study of Sitravatinib Alone or in Combination With Other Anticancer Therapies in Patients With Advanced or Metastatic Solid Malignancies
Enrollment Status: Completed
Publish Date: October 10, 2025
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2025
Intervention Type: Drug
Study Drugs: ONC-392, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid and Hematological Malignancies
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid and Hematological Malignancies
Enrollment Status: Completed
Publish Date: March 04, 2025
A Phase 1b/2a Pilot Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination With Pembrolizumab in HLA-A2+ Participants With NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer
A Phase 1b/2a Pilot Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination With Pembrolizumab in HLA-A2+ Participants With NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: February 23, 2024
Intervention Type: Drug
Study Drugs: Letetresgene autoleucel, Pembrolizumab
Study Phase: Phase 1/Phase 2
Safety Evaluations of Nivolumab (Anti-PD-1) Added To Chemotherapy (CRT) Platforms In Patients With Intermediate And High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma
Safety Evaluations of Nivolumab (Anti-PD-1) Added To Chemotherapy (CRT) Platforms In Patients With Intermediate And High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma
Enrollment Status: Completed
Publish Date: November 29, 2022
Intervention Type: Drug, Radiation
Study Drugs: Nivolumab, Cisplatin, Cetuximab
Study Phase: Phase 1
View 5 Less Clinical Trials

16 Total Publications

Primary Cilia Are Required for Efficient BMP Signaling in Traumatic Heterotopic Ossification.
Primary Cilia Are Required for Efficient BMP Signaling in Traumatic Heterotopic Ossification.
Journal: Biomedicines
Published: December 21, 2025
Similar Doctors
Expertise in
19
conditions
Dr. Manisha Shah
Oncology
Expertise in
19
conditions
Dr. Manisha Shah
Oncology
Referral may be required

Osu Medical Center

320 W 10th Ave, 
Columbus, OH 
 (1139.7 miles away)
614-293-8629
Languages Spoken:
English
See accepted insurances

Manisha Shah is an Oncologist practicing medicine in Columbus, Ohio. Dr. Shah is highly rated in 19 conditions, according to our data. Her clinical expertise encompasses Neuroendocrine Tumor, Thyroid Cancer, Medullary Thyroid Carcinoma, Pancreaticoduodenectomy, and Liver Embolization.

Expertise in
11
conditions
Dr. David Carbone
Oncology
Expertise in
11
conditions
Dr. David Carbone
Oncology
Referral may be required

Ohio State University Hospital-Pavilion

300 W 10th Ave, 
Columbus, OH 
 (1139.7 miles away)
614-366-7744
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Carbone is an Oncologist practicing medicine in Columbus, Ohio. Dr. Carbone is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, and Tissue Biopsy.

Expertise in
22
conditions
Dr. Eric Singer
Oncology
Expertise in
22
conditions
Dr. Eric Singer
Oncology
Referral may be required

Ohio State University Hospital-Pavilion

300 W 10th Ave, 
Columbus, OH 
 (1139.7 miles away)
614-366-7744
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Eric Singer is an Oncologist practicing medicine in Columbus, Ohio. Dr. Singer is highly rated in 22 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Bladder Cancer, Ureterocele, Nephrectomy, and Lymphadenectomy.

Frequently Asked Questions about Dr. Kai He

How do I make an appointment with Dr. Kai He?

You can book an appointment with Dr. Kai He by calling their office at 614-366-7744. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Kai He a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Kai He is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Kai He specialize in?

While Dr. Kai He is a Oncology, they have specific expertise in Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Small Cell Lung Cancer (SCLC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Kai He participate in research or clinical trials?

Yes. Dr. Kai He has published 16 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Kai He's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Kai He accept my insurance?

Dr. Kai He accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 614-366-7744 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. He's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 8 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile